Related Experiment Video
Updated: Jun 9, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer
Meggy Suarez-Carmona1, Niels Halama2
1Department of Cancer Immunology & Cancer Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany; Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany.
None:
Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013